Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly.
We compared the hypothetical effects of the 23-valent polysaccharide pneumococcal vaccine with new vaccines on preventing invasive and noninvasive pneumococcal disease in persons >or=65 years. We estimated how much disease would occur if no polysaccharide vaccine were in use and used this baseline to compare the polysaccharide, a 7-valent conjugate vaccine, and hypothetical common antigen vaccine. The polysaccharide, conjugate, and common antigen vaccines prevented 10.6, 10.7, and 17.7% of invasive disease and 4.3, 5.6, and 10.0% of pneumonia, respectively. Superior effectiveness of new vaccines was dependent upon a presumed longer duration of protection than the 23V-PPV and effectiveness against noninvasive pneumonia. Our results suggest that new vaccines could improve disease prevention.
Fry
Alicia M
AM
Respiratory Diseases Branch, Center for Disease Control and Prevention, Mailstop C-23, 1600 Clifton Road, NE, Atlanta, GA 30333, USA.
Zell
Elizabeth R
ER
Schuchat
Anne
A
Butler
Jay C
JC
Whitney
Cynthia G
CG
D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000502:physiology; D001425:Bacterial Outer Membrane Proteins / Q000737:chemistry / Q000276:immunology; D005260:Female; D006801:Humans; D008297:Male; D011008:Pneumococcal Infections / Q000276:immunology / Q000401:mortality / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage* / Q000276:immunology; D011135:Polysaccharides, Bacterial / Q000008:administration & dosage* / Q000737:chemistry / Q000276:immunology; D012680:Sensitivity and Specificity; D013296:Streptococcus pneumoniae / Q000276:immunology; D016019:Survival Analysis; D016896:Treatment Outcome; D018074:Vaccines, Conjugate / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology
D001425:Bacterial Outer Membrane Proteins; D022242:Pneumococcal Vaccines; D011135:Polysaccharides, Bacterial; D018074:Vaccines, Conjugate